Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology

Basit Öğe Kaydı
dc.authoridharputluoglu, hakan/0000-0001-8537-5941
dc.authoridduran, Ayse Ocak/0000-0002-1703-726X
dc.authoridCihan, Şener/0000-0002-3960-4982
dc.authoridCihan, Şener/0000-0002-3594-3661
dc.authoridBilici, Ahmet/0000-0002-3192-456X
dc.authoridbayoglu, ibrahim vedat/0000-0002-0481-1084
dc.authoridOdabas, Hatice/0000-0002-5757-4705
dc.authorwosidharputluoglu, hakan/ABI-6451-2020
dc.authorwosidYavuzer, Dilek/AAU-5509-2021
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.authorwosidduran, Ayse Ocak/ABA-7090-2021
dc.authorwosidGumus, Mahmut/C-7135-2008
dc.authorwosidCihan, Şener/IXW-9641-2023
dc.authorwosidCihan, Şener/AAW-1956-2021
dc.contributor.authorBilici, Ahmet
dc.contributor.authorOzturk, Turkan
dc.contributor.authorTurkmen, Esma
dc.contributor.authorOdabas, Hatice
dc.contributor.authorCihan, Sener
dc.contributor.authorSelcukbiricik, Fatih
dc.contributor.authorErdogan, Bulent
dc.date.accessioned2024-06-12T11:14:02Z
dc.date.available2024-06-12T11:14:02Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractApproximately 75 % of patients with testicular seminoma present with stage I disease, and the probability of long-term survival approaches 100 %. However, the standard adjuvant treatment for stage I seminoma patients remains controversial, and there is no uniform consensus in the literature. The present study was performed to evaluate treatment preference and outcomes for men with stage I testicular seminoma. From 1997 to 2013, 282 patients with histologically confirmed stage IA and IB testicular seminoma who underwent orchiectomy were included. The outcomes of three management options and survivals were retrospectively analyzed. The prognostic significance of risk factors for relapse on survival was evaluated by univariate and multivariate analysis; in addition, the factors predicting relapse were also evaluated by logistic regression analysis. Of the 282 patients with stage I seminoma, 130 (46.1) received adjuvant radiotherapy (RT), 80 (28.4 %) were treated with adjuvant carboplatin, while the remaining 72 patients (25.5 %) underwent surveillance. At the time of analysis, the median follow-up period of 38.5 months; relapses were observed in 16 patients (22.3 %) on surveillance, in one patient (1.2 %) treated with adjuvant carboplatin and in ten patients (%7.7) who received adjuvant RT. The 5-year disease-free survival (DFS) rate for patients who underwent surveillance was worse than those of patients treated with adjuvant carboplatin and RT (64.2 vs. 97.7 vs. 91.9 %, respectively; p < 0.001). However, the 5-year overall survival (OS) rate for patients on surveillance was similar compared with the adjuvant treatment groups (100 vs. 92.3 vs. 97.4 %, respectively; p = 0.44). Univariate analysis showed that only the treatment approach (surveillance vs. adjuvant carboplatin vs. adjuvant RT) for DFS (p < 0.001), invasion of the rete testis (p = 0.041) and the presence of relapse (p < 0.001) for OS were important prognostic indicators. Multivariate analysis indicated that the treatment strategy for DFS (p < 0.001, HR 0.34) was an independent prognostic factor. Furthermore, a logistic regression analysis showed that adjuvant treatment was found to be an independent factor for predicting relapse (p = 0.004, odds ratio: 0.39). Our results indicate that adjuvant treatment with carboplatin or RT is associated with improved DFS compared with surveillance for men with stage I testicular seminoma after orchiectomy. Moreover, the treatment strategy is an important prognostic indicator for DFS and a predictive factor for relapse. Although adjuvant treatment, especially carboplatin, seems to be a suitable treatment for patients with risk factors for relapse, surveillance is still feasible and the preferred management option after radical orchiectomy in men with stage I seminoma. More reliable predictive factors are needed to make treatment decisions.en_US
dc.identifier.doi10.1007/s00345-015-1492-9
dc.identifier.endpage1622en_US
dc.identifier.issn0724-4983
dc.identifier.issn1433-8726
dc.identifier.issue10en_US
dc.identifier.pmid25605506en_US
dc.identifier.scopus2-s2.0-84942549461en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1613en_US
dc.identifier.urihttps://doi.org/10.1007/s00345-015-1492-9
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23783
dc.identifier.volume33en_US
dc.identifier.wosWOS:000361841900031en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofWorld Journal Of Urologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSeminomaen_US
dc.subjectAdjuvant Treatmenten_US
dc.subjectRadiotherapyen_US
dc.subjectCarboplatinen_US
dc.subjectSurveillanceen_US
dc.subjectSurvivalen_US
dc.subjectCanceren_US
dc.subjectSurveillanceen_US
dc.subjectRisken_US
dc.subjectCarboplatinen_US
dc.subjectManagementen_US
dc.subjectRadiationen_US
dc.subjectUpdateen_US
dc.titleTreatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncologyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu